Asia Healthcare Podcast

JChanPharma

The one and only podcast focused on healthcare in Asia, we talk to healthcare and biotech experts to break down the latest trends and developments in Asia's healthcare space. Sponsored by nobody.

  1. 03/22/2021

    #012 - Pandemic preparedness w/ Lance Little, Managing Director of Roche Diagnostics APAC

    Did you know that roughly only 2% of healthcare spending goes into diagnostic testing? And yet it informs the majority of our clinical decisions. Lance Little, managing director of Roche Diagnostics APAC and board member of APACMed joins me this week to discuss the pandemic preparedness of Asia’s healthcare systems, and the role of diagnostics in the future of healthcare. Topics we explored: - How has Asia responded to the pandemic so far? - What factors can really impact how well a country contain an outbreak? - Is our current healthcare system setup vulnerable to sudden shocks like pandemics? - Are we spending too little on healthcare diagnostics? - How can we build the healthcare systems that can withstand ‘shock events’ for the future? - Are we poised for a digital revolution in healthcare? Useful links: Building Regulatory Agility for Adequate Access to Quality SARS-CoV-2 Test Kits During the Global Pandemic The Critical Role of Diagnostics in COVID-19 Management Follow Roche Diagnostics APAC - https://www.roche.com.sg/ https://www.linkedin.com/showcase/rochediagnosticsasiapacific/ Follow Asia Pacific Medical Technology Association (APACMed): https://apacmed.org/ https://www.linkedin.com/company/asia-pacific-medical-technology-association/ Follow the Asia Healthcare Podcast! Website: https://anchor.fm/asiahealthcare Twitter: @jchanpharma Email: asiahealthcarepodcast@gmail.com Music from https://www.jeffcaylor.com/

  2. 12/04/2020

    #010 - From Biotech Analyst to CEO, w/ Ying Huang, CEO of Legend Biotech

    Ying Huang spent 9 years in drug R&D and 12 years as a biotech analyst. He signed up to be Legend Biotech's CFO, but 17 months later he was named CEO. In this episode, I catch up with Ying about his transition into CEO at Legend. We also talk about cilta-cel and the new clinical trial data the company will be presenting at this year’s American Society of Hematology (ASH) meeting, and his reflections on 2020. * Cilta-cel is an investigational chimeric antigen receptor T (CAR-T) cell therapy, formerly identified as JNJ-4528 in the U.S. and Europe and LCAR-B38M in China, that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and in earlier lines of treatment. Topics we explored: - Ying’s first impression of Legend Biotech at ASCO 2017 - Why Ying decided to join Legend - How has Frank’s departure impacted Legend and his transition as CEO - Cilta-cel’s (LCAR-B38M/JNJ-4528) development and expectations for ASH 2020 - Lessons from 2020 and his advice for future scientists Useful links: Legend Biotech Announces Leadership Transition Legend Biotech CEO detained in China as part of investigation 177 CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma Follow Legend Biotech: Website – https://www.legendbiotech.com/index.php LinkedIn – https://www.linkedin.com/company/legendbiotechco./ Follow the Asia Healthcare Podcast! https://anchor.fm/asiahealthcare Twitter: @jchanpharma Music from https://www.jeffcaylor.com/

  3. 11/02/2020

    #009 - Futureproofing healthcare systems w/ Rachel Frizberg, Area Head of APAC, Roche Pharma

    As of this recording, we are on our way to hitting 45 million cases of Covid-19 worldwide, the majority of those have recovered but new cases are still rising in most countries and if anything, this year’s pandemic has really highlighted how vulnerable our healthcare systems can be. Even before the emergence of Covid-19, many countries faced challenges in providing equitable healthcare access to all of their population. Today on the show, we explore what healthcare systems in the APAC region look like and why it’s important for different stakeholders to work together to find ways to improve the system. In this episode, I am joined by Rachel Frizberg, Area Head of Asia Pacific for Roche Pharma. Originally from the UK, Rachel shares with us what led her to Asia, why she’s passionate about working with different decision makers to improve health equity in the region, and what does ‘futureproofing’ health care systems mean and what will it look like. Topics we explored: - Why chemical manufacturing was not Rachel's calling, and how she found her way to Roche in Asia - What makes health equity challenging in APAC - Differences in healthcare systems across Asia and finding opportunities to bring stakeholders to the table - Relationship building with trust, finding a common goal, and data-driven conversations - What is 'futureproofing' healthcare systems and how can it be achieved? Follow Roche's Futureproofing healthcare initiative: https://futureproofinghealthcare.com/ https://www.roche.com/about/priorities/personalised_healthcare/futureproof.htm Follow the Asia Healthcare Podcast! https://siryn.co/asia-healthcare-podcast https://anchor.fm/asiahealthcare Twitter: @jchanpharma Music from https://www.jeffcaylor.com/

  4. 07/31/2020

    #008 - Japan's Shonan iPark & AI Dynamics

    Science parks – sometimes called research parks, innovation parks, or hi-tech parks – exist to provide an open and collaborative environment for innovative companies to connect and potentially form partnerships to accelerate the research and development of technologies and solutions of the future. But what happens when a global pandemic forces the world into a state of physical distancing? Shonan Health Innovation Park (iPark) is one of the few science and technology ‘hotspots’ in Asia today. Founded in 2018, Takeda Pharmaceuticals transformed its previous Shonan research site into Shonan iPark to create an ecosystem for researchers, industry experts, venture startups, government, and academia to collaborate and co-create cutting-edge technology and health solutions for patients across the world. Toshio Fujimoto, GM of Shonan iPark, joins us to share what the park has accomplished in its first two years and how Covid-19 has impacted its operations this year. We were also delighted to have Rajeev Dutt, president and CEO of AI Dynamics, share with us why he decided to become a member of Shonan iPark and how it has helped his company transition into the biotechnology sector. Topics we explored: - What is the goal of the iPark and what benefits are there to becoming a part of the community? - What are the challenges to building a successful ecosystem? - What types of companies are at iPark and how do companies qualify to become a member? - How is iPark continuing the support its members during Covid-19? - Why is venture capital for the biotech sector so small in Japan? - Why startups such as AI Dynamics decided to join Shonan iPark - How has Covid-19 impacted fundraising activity for startups like AI Dynamics? Follow Shonan Health iPark: Website – https://www.shonan-health-innovation-park.com/en/ LinkedIn – https://www.linkedin.com/company/shonan-health-innovation-park/ Follow AI Dynamics: Website – https://dimensionalmechanics.com/ LinkedIn – https://www.linkedin.com/company/aidynamics/ Follow the Asia Healthcare Podcast! https://siryn.co/asia-healthcare-podcast https://anchor.fm/asiahealthcare Twitter: @jchanpharma Music from https://www.jeffcaylor.com/

5
out of 5
4 Ratings

About

The one and only podcast focused on healthcare in Asia, we talk to healthcare and biotech experts to break down the latest trends and developments in Asia's healthcare space. Sponsored by nobody.